GSK, Genmab Set “Ambitious” Development Plan For HuMax-CD20
GSK signs record $2.1 billion deal with Genmab to commercialize the CD20 antibody for leukemia and rheumatoid arthritis indications.
GSK signs record $2.1 billion deal with Genmab to commercialize the CD20 antibody for leukemia and rheumatoid arthritis indications.